Summary
This study demonstrates that intravitreal injection of Amphiregulin (AREG) or Growth Differentiation Factor 11 (GDF11) promotes significant retinal ganglion cell survival following optic nerve crush injury via Smad2/3 pathway activation, suggesting pharmacological neuroprotection is feasible. However, neither ligand promoted axon regeneration, indicating that Smad2/3 activation may have divergent effects on survival versus regeneration, with implications for treating retinal degenerative diseases such as glaucoma.
Key Findings
- A single intravitreal injection of AREG or GDF11 immediately after optic nerve crush promoted significant RGC survival via Smad2/3 pathway activation.
- AREG expression was significantly reduced in the adult retina 7 days after optic nerve crush, while GDF11 expression remained unchanged post-injury.
- EGFR expression was upregulated only 3 days post-injury, whereas ALK5 expression was consistently upregulated throughout the post-injury time course.
- Neither AREG nor GDF11 promoted RGC axon regeneration, suggesting Smad2/3 activation supports survival but suppresses regeneration.
Categories
Eye Health & Vision: The study investigates neuroprotective effects on retinal ganglion cells (RGCs), which are the photoreceptive output neurons critical for visual function and relevant to conditions like glaucoma.
Author(s)
HS Yoo
Publication Year
2022
Related Publications
Eye Health & Vision
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa
- Melanopsin and rod–cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humans
- Characteristic patterns of dendritic remodeling in early-stage glaucoma: evidence from genetically identified retinal ganglion cell types
- Intrinsically photosensitive melanopsin retinal ganglion cell contributions to the pupillary light reflex and circadian rhythm